Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718446 | 1.00 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15235894 | 1.00 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL16019177 | 0.88 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL13453249 | 0.88 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15099831 | 0.88 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL17718439 | 0.88 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL17287389 | 0.87 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15149989 | 0.87 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL2564604 | 0.87 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL5508735 | 0.87 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | KDM1A 1482/4885MAOB 174/4885MAOA 363/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | KDM1A 3423/4885MAOB 34/4885MAOA 39/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | KDM1A 3423/4885MAOB 34/4885MAOA 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.